Changes in Use of Antidiabetic Medications Following Price Regulations in China (1999-2009) Christine Lu Harvard Medical School and Harvard Pilgrim Health.

Slides:

Advertisements

Similar presentations

Partnerships for Health Reform Utilization and Expenditures on Outpatient Health Care by HIV Positive Individuals in Rwanda PHR Rwanda - Abt Associates.

Advertisements

The Primary Care Crisis: Prospects for Reinvention Kavita K. Patel M.D., M.S. Daniel Fields Elizabeth Leshen The Primary Care Crisis May 4, 2010, Page.

03/10/2006Francis MALHERBE, Eurostat, unit C1 and Alain GALLAIS, OECD, STD/NAFS Review of European and OECD countries experiences Health output methods.

Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.

Health Literacy in Afghanistan Achievements and Way forward Regional Ministerial Meeting for Asia and the Pacific on Promoting Health Literacy 29 and 30.

Health Care Spending Growth

Addressing Addiction and Substance Use in National Health Reform Eric Goplerud, Ph.D. Alliance for Health Care Reform July 17, 2009 Center for Integrated.

Impact of an antidepressant adherence program in a managed care organization Kara Zivin Bambauer, PhD Stephen Soumerai, ScD Alyce Adams, PhD Fang Zhang,

The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.

Exhibit 1. National Health Expenditures per Capita, 1980–2007

THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.

Figure ES-1. How Well Do Different Strategies Meet Principles for Health Insurance Reform? Principles for Reform Tax Incentives and Individual Insurance.

Promising Practices Related To The Prevention, Control and Treatment of Hypertension David J. Hyman, MD, MPH Professor of Medicine and Family & Community.

Minnesota Health Care Market Trends and Strategies for Cost Containment Health Care Transformation Task Force July 30, 2007 Julie Sonier Director, Health.

1 Florida Department of Corrections Update on Health Services Cost Containment Presentation to the Senate Committee on Criminal and Civil Justice Appropriations.

Improving Use of Medicines - Where are we today? Kathleen A Holloway Regional Advisor Essential Drugs and Other Medicines World Health Organisation, South.

NH Insurance Department NH Research and Evaluation Group October 21, 2013 Tyler Brannen Health Policy Analyst.

Interrupted Time Series: What, Why and How Karen Smith An Example From Suicide Research.

Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan Relationship between Tariffs, Prices and Consumption of Interferon.

List of figure titles 1.Estimated percentage of people aged 20 years or older with diagnosed and undiagnosed diabetes, by age group, United States, 2005–2008.

Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD.

The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented.

1 Exploration of Health Care Providers Behavior to Keep Their Revenues after Reduction of Payment Generosity --- A Case of Drug Payment in Taiwan Likwang.

IMPLEMENTATION OF HOSPITAL AUTONOMY: VIETNAM EXPERIENCES Health Strategy and Policy Institute - Vietnam.

Longitudinal Analysis of Market Utilization / Pharmaceutical Sales Data Christine Lu Harvard Medical School and Harvard Pilgrim Health Care Institute WHO.

THE IRRATIONAL USE OF DRUGS IN RURAL CHINA: EVIDENCES FROM TWO PROVINCES Qiang SUN, Jia YIN, Genyong ZUO, Qingyue MENG Center for Health Management & Policy,

Cost Offsets from Recommended Medications for Medicare Beneficiaries with Diabetes AcademyHealth June 9, 2008 Bruce Stuart,* Linda Simoni-Wastila,* Lirong.

THE INAPPROPRIATE SALE OF MEDICATION FOR PEDIATRIC USE IN SIEM REAP PROVINCE, KINGDOM OF CAMBODIA AUTHORS: Sothearith Tiv Ph., Rathi Guhadasan MBBS MRCP.

Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.

1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.

PICO Presentation July 29, 2011 Jaclyn Wakita Pharmacy Resident University Hospital of Northern British Columbia.

Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:

Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences

Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care Trends in the.

3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.

Evaluating the quality of care for patients with type 2 diabetes using the electronic medical record information in Mexico 1 Epidemiology and Health Services.

Stephen Soumerai, Sc.D. Professor Department of Ambulatory Care and Prevention Harvard Medical School and Harvard Pilgrim Health Care Designing Pharmacy.

The Effect of Quality Improvement on Racial Disparities in Diabetes Care Thomas D. Sequist, MD MPH Alyce S. Adams, PhD Fang Zhang, MS Dennis Ross-Degnan,

1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat.

Racial Differences in the Impact of HMO Coverage of Diabetes Blood Glucose Monitors on Self-Monitoring Connie A. Mah, M.S. Department of Ambulatory Care.

Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.

Objective The aim was to investigate the impact of purchasing medicines jointly by the JPD for the four participating parties in the first tender on the.

Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.

Longitudinal Methods for Pharmaceutical Policy Evaluation Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care WHO Collaborating.

Gender and Access to Medicines in 15 Low- and Middle-Income Countries: Does Physician Prescribing for Men and Women Differ? Stephens, Peter (1); Ross-Degnan,

Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from.

Objective The aim was to assess purchasing pharmaceuticals in the public health sector in Jordan through the joint procurement for participating parties.

Response to the crisis - Lithuanian way. Dynamics of Compulsory Health Insurance Fund Budget and Gross Domestic Product (GDP) from 1998 to 2010.

Designing and Managing Medicines Benefits – Goals, Policy Options, Ethical Considerations Anita Katharina Wagner Department of Population Medicine Harvard.

The Role of Disease Management in Medical Research and Quality David Atkins, MD, MPH Agency for Healthcare Research and Quality Disease Management Colloquium,

A FORMATIVE STUDY TO DESIGN AN INTERVENTION INVOLVING MOTHERS, DRUGS VENDORS AND HEALTH WORKERS IN A SELF-PROCESS OF BEHAVIORAL CHANGE FOR RATIONAL DRUG.

Rapid Penetration of COX2 Inhibitors in Non-Steroidal Antiinflammatory Drug Market: an Implication to Hospital Cost Containment Policy Supon Limwattananon,

Impacts of Direct Fee-For- Service Payment Insurance on Access and Use of Drug: An Interrupted Time Series Study on Diabetic Care Inthira Kanchanaphibool,

IMPROVING ECONOMIC PRESCRIBING IN A TEACHING HOSPITAL THROUGH AN EDUCATIONAL STRATEGY TO PROMOTE GENERIC PRESCRIBING.

Overview of China’s health care reform Wen Chen, Ph.D., Professor Fudan School of Public Health March 21, 2016.

Canadian Institute for Health Information Care for Children and Youth with Mental Disorders 1 Michelle Parker CAHSPR.

Quality patients value sustainability partnership Value of generic medicines.

Pharmaceutical Industry Funding Challenges

Italy - Evidence package

Adherence to and persistence with oral antidiabetic medication were evaluated in a sample of 238,372 patients with type 2 diabetes initiating a dipeptidyl.

Abstract Impact of the National Healthcare Reform on Prescribing Patterns of Promotional Targeted Drugs among Thai Physicians Layton MR*, Chadbunchachai.

Abstract No. 452.

Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China Dr Yu Fang, PhD, Anita.

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Abstract Decreased Inappropriate Antibiotic Use Following a Korean National Policy to Prohibit Medication Dispensing by Physicians Sylvia Park, PhD; Stephen.

Funding by ARCH (Boston University)

A LONGITUDINAL POLICY ANALYSIS OF THE IMPACT ON PRESCRIBING PATTERNS AND MEDICATION COST OF A GENERIC DISPENSING POLICY IN A TEACHING HOSPITAL IN THAILAND.

Fig. 2. Quarterly trend of OAC prescription among patients with atrial fibrillation from HIRA-NPS between 2013 and Solid line = results of segmented.

Presentation transcript:

Changes in Use of Antidiabetic Medications Following Price Regulations in China ( ) Christine Lu Harvard Medical School and Harvard Pilgrim Health Care Institute WHO Collaborating Center in Pharmaceutical Policy ICIUM 2011 (Poster 878) WHO Collaborating Center in Pharmaceutical Policy

Acknowledgements  Co-investigators: Dennis Ross-Degnan, Anita Wagner, Bao Liu, Peter Stephens  IMS Health for providing the data  Location of work: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute  Conflict of interest: None

Background – China  High and rapidly growing drug expenditures Medicines = 48% of total health expenditures  24 rounds of price reductions (by 5 to 40%) between 1997 and 2007  Most medicines sold in hospitals  Diabetes is a major burden

Study aim To examine the effects of two targeted price regulations on purchasing of insulin and oral hypoglycemics in Chinese hospitals: 1. Dec 2001: Specific human insulin (non-mixed) and several oral hypoglycemic products 2. Dec 2006: Specific animal insulin (non-mixed) and a large number of oral hypoglycemic products

Methods  Antidiabetic medications: Animal and human insulin products Oral hypoglycemics: alpha-glucosidase inhibitors, biguanides, glinides, sulfonylureas, and thiazolidinediones  Data source: Quarterly data on purchase volume of antidiabetic products collected by IMS Health ( ) Price regulation policies obtained from the China Economic Information Network

Methods  Outcome measures: Sales volume: number of standard units sold per 1000 population per quarter for a specific product Market share: percentage of total market volume represented by price-regulated products Among all antidiabetic products Within specific drug classes  Interrupted time-series design and segmented regression analysis (Wagner AK et al. J Clin Pharm Ther 2002)

Results: Insulin products, 2001 Increase in trend of sales volume (0.06 standard units sold/1000 people/quarter)

Increase in trend of sales volume (0.18 standard units sold/1000 people/quarter) Results: Insulin products, 2006

Results: Oral hypoglycemics, 2001 No observable change in sales volume following price reduction

Results: Oral hypoglycemics, 2006 Increase in trend of sales volume (10.3 standard units sold/1000 people/quarter)

Summary  Dec 2001 price regulation: Increase in market volume trend of insulin products Use of oral hypoglycemic products stable  Dec 2006 price regulation: Increases in market volume trend of both insulin products & oral hypoglycemic products No change in market share of price-regulated insulin and oral hypoglycemic products  Challenges: No information on hospital purchasing prices

Conclusions & research recommendations  China’s targeted approach to drug price reductions may have: Been associated with increases in utilization of antidiabetics Improved access to essential medications OR increased prescribing quantities OR both  Open research questions: Did price and volume changes result in cost savings for Patients? Hospitals? The system? Did price and volume changes result in better quality of care? What are effects of China’s 2009 health care reform which mandates 0% markup on essential medicines in health centers?